Dolutegravir (DTG) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Known as S/GSK1349572 or just \"572\" the drug is marketed as Tivicay by GlaxoSmithKline (GSK). In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process. On August 13, 2013, dolutegravir was approved by the FDA. On November 4, 2013, dolutegravir was approved by Health Canada. On January 16, 2014, Tivicay was approved by the European Commission for use throughout the European Union.

CAS：1051375-16-6
中文别名：
英文别名：(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1\',2\':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1\',2\':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;(4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide;GSK 1349572;S/GSK1349572;Tivicay;
分子式：C20H19F2N3O5
分子量：419.379
精确质量：419.129
Psa：100.87
Logp：1.6816

MDL号：MFCD20488027

外观与性状：白色或淡黄色固体
熔点：188-192°C